Last mentioned: Mar 13, 2026
Lorundrostat PDUFA Date
Target date for FDA decision on Mineralys' lead product candidate.
Nektar Phase 3 Launch
Nektar plans first patient randomization for its Atopic Dermatitis program.
Mineralys NDA Acceptance
FDA accepts Mineralys' NDA for lorundrostat for uncontrolled hypertension.
EHang Record Deliveries
EHang closes Q4 with 100 eVTOL units delivered and first GAAP profit.
HeartBeam FDA Clearance
HeartBeam secures 510(k) clearance for 12-lead ECG synthesis software.
EHang (EH) achieved its first quarterly GAAP profit on record eVTOL deliveries, signaling a commercial inflection point for Advanced Air Mobility. Simultaneously, Vuzix (VUZI) reported a 76% revenue surge in smart glasses and waveguide technology, underscoring robust demand for dual-use augmented reality systems.
NFI Group Inc. reported record-breaking financial results for fiscal 2025, signaling a robust recovery in the global transit and coach manufacturing sector. Meanwhile, Aemetis reported a significant earnings beat despite missing revenue targets as it continues to scale its dairy-based renewable natural gas (RNG) operations.
NFI Group and Aemetis reported record-breaking 2025 financial results, driven by a surge in demand for zero-emission transit and the scaling of renewable natural gas infrastructure. These results underscore a pivotal shift in the industrial and energy sectors toward mature, profitable decarbonized solutions.